Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|May 1, 2005
ISTA seeks FDA OK for phase IIb trial
Irvine, CA—ISTA Pharmaceuticals is asking the FDA for permission to conduct a phase IIb clinical trial for ecabet sodium, a prescription eye drop for treating keratoconjunctivitis sicca (dry eye syndrome).
Advertisement
Irvine, CA-ISTA Pharmaceuticals is asking the FDA for permission to conduct a phase IIb clinical trial for ecabet sodium, a prescription eye drop for treating keratoconjunctivitis sicca (dry eye syndrome).
If the FDA approves ISTA's investigational new drug (IND) application, the company hopes to initiate the trial in the second quarter of 2005. The trial is designed to evaluate corneal and conjunctival staining and tear film break-up time, as well as any ocular symptoms, such as burning or stinging.
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia
2
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
3
Diabetic macular edema: an inflammatory disease in focus
4
AAO 2026: GLP-1RA initiation not linked to anti-VEGF burden in DME
5